Search results
Want an Extra $100 in Annual Dividend Income? Invest $1,320 in These 3 High-Yield Stocks
Motley Fool via Yahoo Finance· 18 hours agoPfizer Shares of Pfizer have lost more than half their value since the stock peaked in late 2021. In...
Regeneron (NASDAQ:REGN): Is This Stock-Split Contender a Strong Buy?
TipRanks via Yahoo Finance· 3 days agoRegeneron (NASDAQ:REGN) stock has more than tripled in value in the past five years, with the price...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 5 days agoTeva has partnered with Sanofi for its anti-TL1A candidate to maximize the value of the asset....
How to buy IPO stock
Bankrate via AOL· 5 days agoNew IPOs often have limited histories and so it can be tough to assess and value them. This is particularly true when a company is in a nascent industry,...
Nvidia surpasses Microsoft to become the largest public company in the world
CNN Business via Yahoo Finance· 5 days agoThe iPhone maker’s market cap slid back below Microsoft’s just a day later. Nvidia completed a...
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
InvestorPlace· 4 days agoWhile investing, the focus is on the top blue-chip stocks to buy that offer growth with stability....
‘The Next Domino To Fall’—Tech Billionaire Primes Bitcoin For A Massive Price Shock
Forbes· 2 days agoHouse hopeful Donald Trump issues a serious warning over a potential U.S. dollar collapse. Subscribe...
3 Meme Stocks to Sell Before E-Trade Gives Roaring Kitty the Boot
InvestorPlace via Yahoo Finance· 6 days agoRoaring Kitty brought meme stocks back to life. His first post in three years in mid-May caused...
AI fever drives Nvidia to world's most valuable company, over Microsoft and Apple
USA TODAY via Yahoo Finance· 5 days agoBlockbuster earnings and broadening investor enthusiasm over AI are supercharging Nvidia's rally. That fervor has been reflected in Nvidia’s market value
Eli Lilly's Growth Prospects Just Got a Huge Upgrade
Motley Fool via Yahoo Finance· 4 days agoAt its peak, donanemab could easily be a blockbuster drug as analysts project it could generate around $5 billion in revenue. There's a lot of upside...